Prevalence of Non-alcoholic Fatty Liver Disease and Risk Factors for Advanced Fibrosis and Mortality in the United States

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Mar 28

PMID 28346543

Citations 126

Authors

Michael H Le

Pardha Devaki

Nghiem B Ha

Dae Won Jun

Helen S Te

Ramsey C Cheung

Mindie H Nguyen

Affiliations

Soon will be listed here.

Abstract

In the United States, non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and associated with higher mortality according to data from earlier National Health and Nutrition Examination Survey (NHANES) 1988-1994. Our goal was to determine the NAFLD prevalence in the recent 1999-2012 NHANES, risk factors for advanced fibrosis (stage 3-4) and mortality. NAFLD was defined as having a United States Fatty Liver Index (USFLI) > 30 in the absence of heavy alcohol use and other known liver diseases. The probability of low/high risk of having advanced fibrosis was determined by the NAFLD Fibrosis Score (NFS). In total, 6000 persons were included; of which, 30.0% had NAFLD and 10.3% of these had advanced fibrosis. Five and eight-year overall mortality in NAFLD subjects with advanced fibrosis was significantly higher than subjects without NAFLD ((18% and 35% vs. 2.6% and 5.5%, respectively) but not NAFLD subjects without advanced fibrosis (1.1% and 2.8%, respectively). NAFLD with advanced fibrosis (but not those without) is an independent predictor for mortality on multivariate analysis (HR = 3.13, 95% CI 1.93-5.08, p<0.001). In conclusion, in this most recent NHANES, NAFLD prevalence remains at 30% with 10.3% of these having advanced fibrosis. NAFLD per se was not a risk factor for increased mortality, but NAFLD with advanced fibrosis was. Mexican American ethnicity was a significant risk factor for NAFLD but not for advanced fibrosis or increased mortality.

Citing Articles

Effects of Metabolic Dysfunction-Associated Steatohepatitis in Alertness, Associative Learning, and Astrocyte Density.

Higarza S, De Anton-Cosio M, Zorzo C, Arias J, Arias N Brain Behav. 2024; 15(1):e70222.

PMID: 39740785 PMC: 11688113. DOI: 10.1002/brb3.70222.

Associations Among Reduced Income, Unhealthy Habits, the Prevalence of Non-Communicable Diseases, and Multimorbidity in Middle-Aged and Older US Adults: A Cross-Sectional Study.

Pereira-Payo D, Pastor-Cisneros R, Mendoza-Munoz M, Carrasco-Marcelo L Healthcare (Basel). 2024; 12(23).

PMID: 39685021 PMC: 11641649. DOI: 10.3390/healthcare12232398.

Advanced Liver Fibrosis Predicts Liver Outcomes in Biopsy-proven Metabolic Dysfunction-associated Steatotic Liver Disease: A U.S.-based Single-center Retrospective Cohort Study.

Lam R, Jain D, Deng Y, Acharya E, Lim J J Clin Transl Hepatol. 2024; 12(12):988-996.

PMID: 39649030 PMC: 11622200. DOI: 10.14218/JCTH.2024.00189.

Extended Review and Updates of Nonalcoholic Fatty Pancreas Disease.

Habas E, Farfar K, Habas E, Rayani A, Elzouki A Saudi J Med Med Sci. 2024; 12(4):284-291.

PMID: 39539795 PMC: 11556510. DOI: 10.4103/sjmms.sjmms_526_23.

NAFLD No More: A Review of Current Guidelines in the Diagnosis and Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Kaylan K, Paul S Curr Diab Rep. 2024; 25(1):5.

PMID: 39535566 DOI: 10.1007/s11892-024-01558-y.

References

Zein C, Unalp A, Colvin R, Liu Y, McCullough A . Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2010; 54(4):753-9. PMC: 3060962. DOI: 10.1016/j.jhep.2010.07.040. View

Lazo M, Hernaez R, Eberhardt M, Bonekamp S, Kamel I, Guallar E . Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178(1):38-45. PMC: 3698993. DOI: 10.1093/aje/kws448. View

Neuschwander-Tetri B, Clark J, Bass N, Van Natta M, Unalp-Arida A, Tonascia J . Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52(3):913-24. PMC: 3070295. DOI: 10.1002/hep.23784. View

Kim C, Younossi Z . Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008; 75(10):721-8. DOI: 10.3949/ccjm.75.10.721. View

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

Unalp-Arida A, Ruhl C . Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology. 2015; 63(4):1170-83. PMC: 4805455. DOI: 10.1002/hep.28390. View

Chitturi S, Farrell G, Hashimoto E, Saibara T, Lau G, Sollano J . Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007; 22(6):778-87. DOI: 10.1111/j.1440-1746.2007.05001.x. View

Musso G, Gambino R, Cassader M, Pagano G . Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010; 43(8):617-49. DOI: 10.3109/07853890.2010.518623. View

Wallace T, Levy J, Matthews D . Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6):1487-95. DOI: 10.2337/diacare.27.6.1487. View

10.

Meffert P, Baumeister S, Lerch M, Mayerle J, Kratzer W, Volzke H . Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am J Gastroenterol. 2014; 109(9):1404-14. DOI: 10.1038/ajg.2014.155. View

11.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

12.

Angulo P, Hui J, Marchesini G, Bugianesi E, George J, Farrell G . The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007; 45(4):846-54. DOI: 10.1002/hep.21496. View

13.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMC: 1636651. DOI: 10.1186/1471-230X-6-33. View

14.

Koehler E, Schouten J, Hansen B, Hofman A, Stricker B, Janssen H . External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013; 11(9):1201-4. DOI: 10.1016/j.cgh.2012.12.031. View

15.

Johnson C, Paulose-Ram R, Ogden C, Carroll M, Kruszon-Moran D, Dohrmann S . National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital Health Stat 2. 2014; (161):1-24. View

16.

Zipf G, Chiappa M, Porter K, Ostchega Y, Lewis B, Dostal J . National health and nutrition examination survey: plan and operations, 1999-2010. Vital Health Stat 1. 2014; (56):1-37. View

17.

Machado M, Cortez-Pinto H . Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2012; 58(5):1007-19. DOI: 10.1016/j.jhep.2012.11.021. View

18.

Yang B, Wu W, Fang K, Wang Y, Huo T, Huang Y . External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS One. 2015; 10(3):e0120443. PMC: 4363626. DOI: 10.1371/journal.pone.0120443. View

19.

Adams L, Lymp J, Sauver J, Sanderson S, Lindor K, Feldstein A . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1):113-21. DOI: 10.1053/j.gastro.2005.04.014. View

20.

Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View